Publications - Miriam Kim Lab

Browse through our latest manuscripts

Key Publications

Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity

Rubina Thomas, Julie K. Ritchey, John F. DiPersio, Miriam Y. Kim. Molecular Therapy, 2025.

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity

Miriam Y. Kim, Reyka Jayasinghe, Jessica M. Devenport, Julie K. Ritchey, Michael P. Rettig , Julie O’Neal , Karl W. Staser, Krista M. Kennerly, Alun J. Carter, Feng Gao, Byung Ha Lee , Matthew L. Cooper & John F. DiPersio. Nature Communication, 2022.

CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy

Miriam Y. Kim, Matthew L. Cooper, Miriam T. Jacobs, Julie K. Ritchey, Julia Hollaway, Todd A. Fehniger, and John F. DiPersio. JCI Insight, 2021.

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia

Miriam Y. Kim, Kyung-Rok Yu, Saad S. Kenderian, Marco Ruella, Shirley Chen, Tae-Hoon Shin, Aisha A. Aljanahi, Daniel Schreeder, Michael Klichinsky, Olga Shestova, Miroslaw S. Kozlowski, Katherine D. Cummins, Xinhe Shan, Maksim Shestov, Adam Bagg, Jennifer J.D. Morrissette, Palak Sekhri, Cicera R. Lazzarotto, Katherine R. Calvo, Douglas B. Kuhns, Robert E. Donahue, Gregory K. Behbehani, Shengdar Q. Tsai, Cynthia E. Dunbar, Saar Gill. Cell, 2018.

CXCR4 to improve both T cell homing and function

Miriam Y. Kim. Blood, 2023.

Making normal hematopoiesis invisible to CAR T cells

Miriam Y. Kim. Trends in Cancer, 2023.

Complete List of Publications

Immune Adjuvant Therapy With Interleukin-7 in a Lymphopenic Patient With Aplastic Anemia and Mucormycosis
Crees ZD, Patel DA, Dram A, Kim M, Bern MD, Eberly AR, Augustin K, Hotchkiss RS, DiPersio JF.
Crit Care Explor 2023 Oct 19;5(10):e0990.
Making normal hematopoiesis invisible to CAR T cells
Kim MY.
Trends Cancer 2023 Dec;9(12):983-984.
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Xiang J, Devenport JM, Carter AJ, Staser, KW, Kim MY, O’ Neal J, Ritchey JK, Rettig MP, Gao F, Rettig G, Turk R, Lee BH, Cooper ML, DiPersio JF.
Leukemia 2023 Dec;37(12):2448-2456.
CXCR4 to improve both T cell homing and function
Kim MY.
Blood 2023 May 25;141(21):2546-2547.
Flotetuzumab and Other T-Cell Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells
Rimando JC, Chendamarai E, Rettig MP, Jayasinghe RG, Christopher M, Ritchey JK, Christ S, Kim M, Bonvini E, DiPersio JF.
Blood. 2023 Apr 6;141(14):1718-1723.
A Long-Acting Interleukin-7, rhIL-7-hyFc, Enhances CAR T Cell Expansion, Persistence, and Anti-Tumor Activity
Kim MY, Jayasinghe R, Devenport JM, Ritchey JK, Rettig MP, O'Neal J, Staser KW, Kennerly KM, Carter AJ, Gao F, Lee BH, Cooper ML, DiPersio JF.
Nat Commun 2022 June 13;13(1):3296.
Decitabine Salvage for Tumor Protein p53-Mutated, Relapsed/Refractory Acute Myeloid Leukemia After Cytotoxic Induction Therapy
Ferraro F, Gruszczynska A, Ruzinova MB, Miller CA, Percival ME, Uy GL, Pusic I, Jacoby MA, Christopher MJ, Kim MY, Westervelt P, Cashen AF, Schroeder MA, DiPersio JF, Abboud CN, Wartman LD, Gao F, Link DC, Ley TJ, Welch JS.
Haematologica 2022 Jul 1;107(7):1709-1713.
CD7 deleted hematopoietic stem cells can restore immunity after CAR T cell therapy
Kim MY, Cooper ML, Jacobs MT, Ritchey JK, Hollaway J, Fehniger TA, DiPersio JF.
JCI Insight 2021 Aug 23;6(16):e149819.
Prediction and Validation of Hematopoietic Stem and Progenitor Cell Off-Target Editing in Transplanted Rhesus Macaques
AlJanahi AA, Lazzarotto CR, Chen S, Shin TH, Cordes S, Fan X, Jabara I, Zhou Y, Young DJ, Lee BC, Yu KR, Li Y, Toms B, Tunc I, Hong SG, Truitt LL, Klermund J, Andrieux G, Kim MY, Cathomen T, Gill S, Tsai SQ, Dunbar CE.
Mol Ther 2022 Jan 5;30(1):209-222.
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas10. Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila ML, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, Kahl B, Kim M, Cooper ML, DiPersio JF, Berrien-Elliott MM, Fehniger TA.
Blood 2020 Nov 12;136(20):2308-2318.
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O’Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S.
Nature Biotechnology 2020 Aug;38(8):947-953.
Unlabeled Competitor Antibody to Reduce Nonlinear Signal Spillover in Mass Cytometry
Sekhri P, Kim MY, Behbehani GK.
Cytometry A 2019 Aug;95(8):898-909.
Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia
Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S.
Cell 2018 May 31;173(6):1439-1453.
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT
Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ jr, Druker BJ, Tyner JW, Gill PS.
Blood Adv. 2017 Aug 28;1(20):1635-1644.
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma
Kim MY, Sposto R, Swaika A, Asano H, Alamgir A, Chanan-Khan A, Ailawadhi S.
Oncology 2014; 87: 224-231.
Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer
Kim M, Agarwal S, Tripathy D.
Current Opinion in Obstetrics and Gynecology 2014 Feb;26(1): 27-33.
Major non-ABO incompatibility caused by anti-Jka antibody in a patient before allogeneic hematopoietic stem cell transplantation
Kim MY, Chaudhary P, Shulman I, Pullarkat V.
Immunohematology 2013; 29: 11-14.